GARDP will work largely as a virtual R&D initiative through direct partnerships and multi-stakeholder collaborations, including with academia, industry, international organizations and governments. Working with patented and non-patented drug candidates, GARDP will follow DNDi’s access-driven intellectual property policy in its agreements. While maintaining a clear focus and strategy for all its programmatic interventions,
GARDP will develop partnership models tailored to the capacity and ability of actors involved: in certain programmes, GARDP will need to be actively driving and implementing R&D programmes, while in others, equitable partnerships will be sought whereby GARDP brings in the appropriate amount of funding, direction, and support. All GARDP funding will be linked to the need to develop and make available affordable products that answer to public health needs.
A global collaboration
Partnerships with Governments, academia, research centres and industry are at the heart of GARDP’s work. Without their support, GARDP would not have been able to make the progress it has made so far.
• University of Antwerp
• REPAIR Impact Fund
Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
• All India Institute of Medical Sciences (AIIMS)
• Penta Foundation
• Kenyan Medical Research Institute (KEMRI)
• Institut Pasteur Korea
• Department of Infectious Diseases,
• National Institute for Communicable Diseases (NICD)
• WHO Collaborating Centre for Gonorrhoea and other sexually transmitted infections,
• European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
• Foundation for Innovative New Diagnostics (FIND)
• Sandoz, the Novartis generics division
• Bureau of AIDS, TB, and STIs
• British Society of Antimicrobial Chemotherapy (BSAC)
• American Society of Microbiology (ASM)
GARDP is collaborating with research centres on specific studies in the following countries:
Bangladesh, Brazil, China, Greece, India, Italy, Kenya, The Netherlands, South Africa, Thailand, Vietnam, and Uganda, United States.